Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Hepatitis C

Needle and syringe programmes cost effective in reducing HCV transmission

Study shows needle and syringe programmes reduce transmission of hepatitis C while delivering cost savings.

Box of needles and syringes

Source: Shutterstock.com

The findings support the continued funding of needle and syringe programme services in the UK, researchers say

Needle and syringe programmes (NSPs) are a highly cost-effective means of reducing hepatitis C virus (HCV) transmission, research published in Addiction (23 January 2019) has shown[1].

Researchers used NHS data from three regions with different levels of HCV infection among people who inject drugs: Dundee, Scotland (26%); Walsall, Staffordshire (18%); and Bristol (45%). They modelled the effects of current NSP provision over 50 years, compared with a "counterfactual scenario" where NSPs are removed for 10 years and then returned to existing levels for 40 years.

The researchers found that NSPs were associated with a cost saving of £159,712 in Bristol and £2.5m in Dundee. In Walsall, NSPs were associated with an increased cost of £114,442. However, this gained 192 quality-adjusted life years (QALYs), leading to a cost per QALY gained of only £596.

The researchers said that the findings supported the continued funding of NSP services in the UK and elsewhere, noting that they are probably generalisable to other high-income countries with comparable HCV prevalence.

“We hope that Public Health England, and local government commissioners and policymakers, will take note and continue to commission NSPs, which are currently under threat of funding cuts,” said lead author Zoe Ward from the University of Bristol.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206202

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.